115.30
price up icon1.37%   1.56
 
loading
Schlusskurs vom Vortag:
$113.74
Offen:
$112.4
24-Stunden-Volumen:
1.96M
Relative Volume:
1.19
Marktkapitalisierung:
$243.56B
Einnahmen:
$55.19B
Nettoeinkommen (Verlust:
$13.65B
KGV:
16.81
EPS:
6.86
Netto-Cashflow:
$16.81B
1W Leistung:
-2.04%
1M Leistung:
-6.34%
6M Leistung:
+10.10%
1J Leistung:
+2.85%
1-Tages-Spanne:
Value
$112.34
$115.54
1-Wochen-Bereich:
Value
$112.34
$117.78
52-Wochen-Spanne:
Value
$96.06
$124.83

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
75,883
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2025-07-17
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.30 220.18B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.33 664.39B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.33 396.75B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
195.22 333.89B 58.33B 3.76B 15.39B 2.10
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.29 196.16B 63.62B 16.41B 17.04B 6.49

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Herabstufung UBS Buy → Neutral
2025-02-12 Eingeleitet Morgan Stanley Underweight
2025-02-04 Hochstufung Deutsche Bank Hold → Buy
2024-12-04 Herabstufung HSBC Securities Hold → Reduce
2024-09-11 Herabstufung BofA Securities Buy → Neutral
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Aug 01, 2025

Pharma Stocks Slump on Presidential Ultimatum To Cut Prices - Morningstar

Aug 01, 2025
pulisher
Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025
pulisher
Jul 31, 2025

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate - Benzinga

Jul 31, 2025
pulisher
Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025
pulisher
Jul 17, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar

Jul 17, 2025
pulisher
Jul 15, 2025

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Jul 15, 2025
pulisher
Jul 10, 2025

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Jul 10, 2025
pulisher
Jul 03, 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Jul 03, 2025
pulisher
Jul 01, 2025

Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com

Jul 01, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com

Jun 16, 2025
pulisher
Jun 11, 2025

NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com

Jun 11, 2025
pulisher
Jun 10, 2025

The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com

Jun 10, 2025
pulisher
Jun 03, 2025

Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com

Jun 03, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 28, 2025

Why Value Investing Has Worked Better Outside the US - Morningstar

May 28, 2025
pulisher
May 26, 2025

Which Industries are shaken when Trump's tariff stick swings towards the EU? - 富途牛牛

May 26, 2025
pulisher
May 22, 2025

Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com

May 22, 2025
pulisher
May 19, 2025

Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement

May 19, 2025
pulisher
May 15, 2025

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com

May 14, 2025
pulisher
May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025
pulisher
Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up - Zacks Investment Research

Apr 29, 2025
pulisher
Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general MRK
$79.29
price up icon 1.50%
drug_manufacturers_general NVO
$48.19
price up icon 2.38%
$296.88
price up icon 0.60%
$195.22
price up icon 3.28%
$113.18
price up icon 0.79%
Kapitalisierung:     |  Volumen (24h):